Cambridge Research Biochemicals (CRB) has licensed rights to a system that – it claims – will let biopharmas identify the best delivery peptides more quickly.
Roche has agreed to research, develop and commercialize Inovio Pharmaceuticals' vaccine delivery tech as well as its multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.
The US FDA approval of the new quadrivalent flu vaccine in June has not quite given manufacturers enough time to meet demand expectations, as production time can take up to about six months.
A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.
Biopharma researchers will be able to use a new technology to explore biomarkers and pathways with more sensitivity and precision to create new diagnostics and improved oncology, neurology, cardiology and other therapies.
Bioreliance has launched an updated version of its mutagenicity service after conducting studies that confirmed its Big Blue Mouse assay still meets OECD standards.
Eli Lilly has extended its collaboration with Immunogen to use its antibody-drug conjugate (ADC) technology for development of a specific antigen target.
Rani Therapeutics announced Wednesday that it has closed its Series B round of funding after pulling in more than $10m from Google Ventures, InCube Ventures and VentureHealth, a healthcare crowdfunding portal.
Investors on Tuesday seemed a little less sure of biopharma behemoth Amgen’s decision to purchase cancer specialist Onyx for more than $10B over the weekend.
The new UK biomanufacturing hub will help BioPharmas cut costs and let those developing novel biodrugs assess manufacturability according to the Centre for Process Innovation (CPI).
Stemcell Technologies will use BioLife Solutions’ cryopreservation media to ship its new range of stem cell based products under an expanded agreement.
GlaxoSmithKline is gambling $50M on a venture capital fund that will invest in 20 projects that pioneer bioelectric drugs and technologies that aim to target individual nerve fibres or specific brain circuits to treat an array of conditions.
New flexible vaccine technology could pave the way for pneumococcal, TB and staphylococcus aureus vaccines that are cheaper to produce and more effective.
PharmAthene and Theraclone Sciences announced plans to merge and continue the joint development of monoclonal antibodies (mAbs) and vaccines on the verge of progressing to Phase II and III trials.
The US National Institutes of Health (NIH) announced this week that the famous HeLa genomic sequence data will continue to be available for scientists worldwide, though they will have to apply for access to the data.
Lonza has granted access to its potency boosting expression system to antibody developer Sorrento Therapeutics just days after a signing a similar deal with Pfizer.
GlaxoSmithKline says MAbs (monoclonal antibodies) will play an important part in its future pipeline as it licenses and internalizes a discovery tech platform from Adimab.
Making better CHO cell lines for biomanufacturing may soon be a more precise task according to the team behind the draft Chinese hamster genome published last week.
A new genetically modified strain of E. Coli cells could create enough protein for downstream production without the need for the challenging endotoxin removal steps that are currently employed.
Harbour Antibodies has received a double boost this week raising $3.3m (€2.5m) for its transgenic H2L2 mice technology and adding Pfizer to its list of clients.
Europe may soon approve the first biologic made according to quality by design (QbD) principles, but opinions are still split over whether the approach should even be applied to biopharmaceuticals.
Could a genetically engineered adenovirus really spark a simian revolution and make chimps our masters? BioPharma-Reporter.com looks at the ‘science’ of the 2011 movie “Rise of the Planet of the Apes.”
Keeping up with the latest technology news is a must for biomanufacturers according to an MIT Professor who told BioPharma-Reporter.com new advances in microtechnologies could help address process development challenges.
After patent expiration led to facility shuttering and cutbacks, Irish manufacturing will receive a $130m (€100m) boost to prepare for Pfizer’s new pipeline, the company says.
Primate research is still vital to drug development say CROs after US NIH announces plan to reduce the number of chimps it uses in preclinical testing.
Aesica's new Technical Director talks CMO flexibility and Catalent appoints new delivery unit head - welcome to Outsourcing-Pharma's People on the Move.
US scientists claim their combination of a novel nanoparticle production platform and innovative spray coating technology paves the way for improved drug, biologic and vaccine targeting.
Avanir Pharmaceuticals has bought North American rights to OptiNose’s novel intranasal delivery system to treat acute migraines, which is expected to be filed for US FDA approval by early 2014.
A consortium of European vaccine experts, including the Swiss CRO Preclin Biosystems, has received almost €5.5m ($7.1m) from the EU to develop a vaccine against the deadly MRSA bacteria.
Critical Pharmaceuticals says its protein and peptide delivery technologies offer long acting injectables and greater compliance, saving money and easing patient administration.
In a momentous first for both countries, regulatory officials from China and Taiwan sat down at the same table on Tuesday and discussed their relatively similar ideas around the regulation of drug approvals.
BMS have appointed a new director and ex Shire-CEO joins Questcor - yes, you've guessed it, it's in-Pharmatechnologist.com's weekly pharma people round-up.
The Brazilian Government is to fund a new facility to produce the Protalix-Pfizer Gaucher's disease drug Uplyso as part of a supply and tech transfer deal worth $280m (€212m).
Phyton Biotech has received European approval for a version the cancer drug API docetaxel whose production does not rely on the scarce yew tree extract used in traditional manufacturing methods.
Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.
Lonza has launched a service to help biopharmas decide if promising protein drug candidates are worth developing, from an immunogenicity and manufacturing standpoint.
Catalent says customers are applying controlled release technology to transform drugs into better treatments across all stages of development as it expands its Kentucky manufacturing site.
Biosimilar developers such as Mylan and Pfizer are taking issue with FDA draft guidance that in some circumstances could extend biosimilar development timelines and discourage their development.